Nuances in the Management of Older People With Multiple Myeloma.
Date
2016-06ICR Author
Author
Pawlyn, C
Gay, F
Larocca, A
Roy, V
Ailawadhi, S
Type
Journal Article
Metadata
Show full item recordAbstract
Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age. Yet, the population of elderly patients is heterogeneous: older patients are more likely to have comorbidities and frailties complicating both their initial diagnosis and subsequent management, but these are not consistent across the group. Furthermore, patients with comorbidities and frailty are generally underrepresented in clinical trials. Despite the survival of myeloma patients increasing following the introduction of novel agents, older patients continue to have worse outcomes with increased treatment-related toxicity. Treatment tolerability is not defined by age alone, rather a combination of age, physical function, cognitive function, and comorbidities. These factors all influence patients' tolerability of treatment and therefore treatment efficacy and should also be considered when reviewing the results of clinical trials. It is the nuances of determining how these factors interact that should influence initial treatment and ongoing management decisions and these will be discussed here.
xmlui.dri2xhtml.METS-1.0.item-oa-location
https://iris.unito.it/retrieve/handle/2318/1617904/277857/Nuances%20in%20the%20Management%20of%20Older%20People%20With%20Multiple%20Myeloma.docxCollections
Subject
Humans
Multiple Myeloma
Peripheral Nervous System Diseases
Hematologic Diseases
Thalidomide
Dexamethasone
Antineoplastic Agents, Hormonal
Treatment Outcome
Drug Therapy, Combination
Activities of Daily Living
Aged
Aged, 80 and over
Venous Thromboembolism
Proteasome Inhibitors
Research team
Myeloma Biology and Therapeutics
Language
eng
License start date
2016-06
Citation
Current hematologic malignancy reports, 2016, 11 (3), pp. 241 - 251